Diverse treatment outcomes were observed in Sq-NSCLCs with other FGFR variants: SD (4.1 months PFS and 20% tumor shrinkage) was reported in one patient (6.6%) with simultaneous FGFR1 missense variants: D93Y and H841Y (23), whereas no response was reported in a patient (1/27, 1.4%) with FGFR3 fusion (11). This evidence concerns the gene FGFR3 and neoplasm.